Patents by Inventor Haritha SAMARANAYAKE

Haritha SAMARANAYAKE has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Chloride-Inducible Prokaryotic Expression System
    Publication number: 20220127629
    Abstract: The invention is directed to recombinant bacteria, a recombinant plasmid, a pharmaceutical composition and a kit as well as the use of a reconstitution medium comprising chloride ions to reconstitute the recombinant bacteria.
    Type: Application
    Filed: March 4, 2019
    Publication date: April 28, 2022
    Inventors: Thomas Wirth, Juha Yrjänheikki, Haritha Samaranayake, Hanna-Riikka Kärkkäinen, Jere Kurkipuro, Igor Mierau, Wesley Smith
  • Recombinant probiotic bacteria
    Patent number: 10738315
    Abstract: The invention is directed to recombinant probiotic bacteria, especially for use in the treatment of an inflammatory skin dysfunction, as well as a method for treating an inflammatory skin dysfunction.
    Type: Grant
    Filed: November 2, 2015
    Date of Patent: August 11, 2020
    Assignee: Aurealis Oy
    Inventors: Thomas Wirth, Juha Yrjänheikki, Haritha Samaranayake, Dirk Weber, Igor Mierau, Peter Allard Bron, Herwig Bachmann
  • Transgene-Cytotoxic Combination Therapy
    Publication number: 20200101100
    Abstract: A viral gene therapy combination therapy for cancer, using a virus to deliver a gene to a human patient, where the gene expresses a polypeptide which is not native to the wild-type virus, yet which is nonetheless therapeutically useful when administered in combination with a chemotherapeutic agent.
    Type: Application
    Filed: October 25, 2019
    Publication date: April 2, 2020
    Applicant: Gliotherapy Limited
    Inventors: Haritha SAMARANAYAKE, Seppo YLA-HERTTUALA, Ann-Marie MAATTA, Jere KURKIPURO
  • Recombinant Probiotic Bacteria
    Publication number: 20180135062
    Abstract: The invention is directed to recombinant probiotic bacteria, especially for use in the treatment of an inflammatory skin dysfunction, as well as a method for treating an inflammatory skin dysfunction.
    Type: Application
    Filed: November 2, 2015
    Publication date: May 17, 2018
    Inventors: Thomas Wirth, Juha Yrjänheikki, Haritha Samaranayake, Dirk Weber, Igor Mierau, Peter Allard Bron, Herwig Bachmann
  • Combination Therapy For Cancer
    Publication number: 20170348345
    Abstract: A method of treating brain cancer in an immune-competent human patient by administering ternozolornide to the immune-competent human patient, the improvement comprising administering to said immune-competent human patient a viral vector.
    Type: Application
    Filed: July 10, 2017
    Publication date: December 7, 2017
    Inventors: Haritha SAMARANAYAKE, Jere PIKKARAINEN, Ann-Marie MAATTA, Seppo YLA-HERTTUALA
  • Combination Therapy for Cancer
    Publication number: 20130331442
    Abstract: An agent comprises a vector having a functional gene, a prodrug which can be converted into a cytotoxic agent by an expression product of the gene, and another cytotoxic agent, as a combined preparation for simultaneous, sequential or separate use in the therapy of cancer or of a disease characterised by an impaired mismatch repair (MMR) pathway, wherein the dosage regimen comprises beginning another cytotoxic agent therapy no later than 7 days after the prodrug therapy has finished.
    Type: Application
    Filed: August 14, 2013
    Publication date: December 12, 2013
    Applicant: FINVECTOR VISION THERAPIES LTD
    Inventors: Haritha SAMARANAYAKE, Jere PIKKARAINEN, Ann-Marie MAATTA, Seppo YLA-HERTTUALA
  • Combination Therapy for Cancer
    Publication number: 20130310444
    Abstract: An agent comprises a vector having a functional gene, a prodrug which can be converted into a cytotoxic agent by an expression product of the gene, and another cytotoxic agent, as a combined preparation for simultaneous, sequential or separate use in the therapy of cancer or of a disease characterised by an impaired mismatch repair (MMR) pathway, wherein the dosage regimen comprises beginning the another cytotoxic agent therapy no later than 7 days after the prodrug therapy has finished.
    Type: Application
    Filed: January 18, 2012
    Publication date: November 21, 2013
    Applicant: Ark Therapeutics, Ltd.
    Inventors: Haritha Samaranayake, Jere Pikkarainen, Ann-Marie Maatta, Seppo Yla-Herttuala
  • Combination Therapy for Cancer
    Publication number: 20130296407
    Abstract: An agent comprises a vector having a functional gene, a prodrug which can be converted into a cytotoxic agent by an expression product of the gene, and another cytotoxic agent, as a combined preparation for simultaneous, sequential or separate use in the therapy of cancer or of a disease characterised by an impaired mismatch repair (MMR) pathway, wherein the dosage regimen comprises beginning another cytotoxic agent therapy no later than 7 days after the prodrug therapy has finished.
    Type: Application
    Filed: May 1, 2013
    Publication date: November 7, 2013
    Applicant: ARK THERAPEUTICS, LTD.
    Inventors: Haritha SAMARANAYAKE, Jere PIKKARAINEN, Ann-Marie MAATTA, Seppo YLA-HERTTUALA